EuroBiotech:​​​ ​​​More​​​ ​​​Articles​​​ ​​​of​​​ ​​​Note

Newspapers

> Shares in AB Science climbed 13% after the French biotech posted phase 3 data on masitinib in amyotrophic lateral sclerosis. The higher dose of the tyrosine kinase inhibitor outperformed the placebo in terms of change from baseline on the revised Amyotrophic Lateral Sclerosis Functional Rating Scale, resulting in the study meeting its primary endpoint. AB Science filed for approval of masitinib in the indication in Europe last year. Release

> Advicenne closed a €16 million ($17 million) round. The investment will enable Advicenne to wrap up a phase 3 trial of potassium bicarbonate-potassium citrate fixed dose combination ADV7103 in patients with the orphan disease renal tubulopathy later this year. Advicenne plans to use some of the remaining money to develop ADV7103 in another renal disease. Statement

> SalvaRx invested in Rift Biotherapeutics. The $1 million (€930,000) investment gives SalvaRx a 30% stake in the non T cell based immunotherapy player. SalvaRx, a cancer fund backed by biotech investor Jim Mellon, is also adding two people to Rift’s board: Ex-Bristol-Myers Squibb oncology R&D chief Ian Walters and former AstraZeneca CMO Briggs Morrison. Release

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.

> Argenx teamed up with Broteio Pharma to develop an antibody against autoimmune diseases. The project will use argenx’s research capabilities to take the complement-targeted antibody to preclinical proof of concept. Once those data are available, argenx will decide whether to license the asset, which is sees complementing its lead candidate ARGX-113. Statement

> Minoryx Therapeutics completed a phase 1 trial of its lead candidate MIN-102. The trial found the X-linked adrenoleukodystrophy asset was well tolerated in healthy volunteers. Minoryx plans to move the PPAR gamma agonist into a phase 2/3 trial in the coming months on the strength of the data. Release

> Galapagos moved another potential component of its planned triple-hit cystic fibrosis drug into the clinic. The phase 1 will assess the safety, tolerability and pharmacokinetics of the potentiator GLPG3067, both as a monotherapy and in combination with GLPG3067 and GLPG2222. AbbVie, Galapagos’ partner in cystic fibrosis, made a $7.5 million (€7.0 million) milestone payment in relation to the start of the phase 1. Statement